Clinical trial · Observational
Function of Platelets Used for Transfusions
Flödescytometrisk utvärdering av Den Blodstillande förmågan Hos Trombocyter Avsedda för Transfusion
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cytotoxic treatment for malignant hematologic disorders often casue thrombocytopenia that can result in life threatening bleedings. This is prevented by platelet transfusions but these can cause serious transfusion reactions and thus the number of transused platelet concentrates should be limited. It is therefore important that the platelet concentrates contain functional platelets with long circulation time in the bloodstream. We have developed a method with flow cytometry to measure platelet function markers. It allows us to determine which pathways that are initiated upon activation. The aim of this project is to assess to what degree spontaneous activation of platelets as well as their activation capacity affects the transfusion response (i.e. uptake in the circulation and circulation time) in the recipient. The hypothesis is that transfusion of platelets with low spontaneous activation and high activation capacity will lead to a higher transfusion response in the recipient.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Thrombocytopenia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Platelet transfusion | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Corrected count increment (CCI)
- timeFrame
- 1- and 24 hours after transfusion.
- description
- CCI relates the increase in platelet concentration in participants after transfusion to the number of platelets transfused and the participants blood volume.
- measure
- Spontaneous and agonist induced expression of platelet activation markers on platelets in platelet concentrates.
- timeFrame
- Measured on the day of transfusion prior to transfusion.
- description
- Percentage of platelets expressing P-selectin, LAMP-1, phosphatidylserine and the active conformation of fibrinogen receptor.
- measure
- Spontaneous and agonist induced formation of platelet subpopulations in platelet concentrates.
- timeFrame
- Measured on the day of transfusion prior to transfusion.
- description
- Percentage of normal sized platelets, small platelets and platelet fragments (microparticles).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participant undergoing treatment for malignant hematologic disorders * Thrombocytopenia * Require platelet transfusion Exclusion Criteria: \- Participant requiring HLA-matched platelet transfusions.
References
Publications (0)
Data not yet available